Clinical Potential of Targeting Fibroblast Growth Factor‐23 and αKlotho in the Treatment of Uremic Cardiomyopathy

Clinical Potential of Targeting Fibroblast Growth Factor‐23 and αKlotho in the Treatment of Uremic Cardiomyopathy

Abstract Chronic kidney disease is highly prevalent, affecting 10% to 15% of the adult population worldwide and is associated with increased cardiovascular morbidity and mortality. As chronic kidney disease worsens, a unique cardiovascular phenotype develops characterized by heart muscle disease, in...

Full description

Bibliographic Details
Main Authors: Jonathan P. Law, Anna M. Price, Luke Pickup, Ashwin Radhakrishnan, Chris Weston, Alan M. Jones, Helen M. McGettrick, Winnie Chua, Richard P. Steeds, Larissa Fabritz, Paulus Kirchhof, Davor Pavlovic, Jonathan N. Townend, Charles J. Ferro
Format: Article
Language:English
Published: Wiley 2020-04-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
αKlotho
cardiorenal syndrome
FGF23
fibroblast growth factor
growth factor
kidney
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.120.016041

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.120.016041

Similar Items